TMTC2

Across TCGA pan-cancer cohorts, TMTC2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMTC2 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TMTC2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMTC2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where TMTC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.260	0.614	.014	9	view →
LSCC	DFS	Tertile	III,IV	0.970	0.540	.022	7	view →
LUAD	DFS	Tertile	All	0.774	1.000	.016	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TMTC2–PDAC (DFS)

Open the PDAC breakdown →